EP300 and breast carcinoma: Our lab further clarified the underlying mechanisms of its activity: carnosol was found to target STAT3 [90] and p300 [91] to proteasomal degradation in an ROS-dependent manner and to function as a specific inhibitor of p300 in breast cancer [91].